Phase 1 trial of COVID-19 antibody drug begins
By MYBRANDBOOK
US Pharma company Eli Lilly has started dosing participants in the Phase I clinical trial of antibody therapy to treat coronavirus. This is said to be the world’s first study to assess an antibody treatment for the disease.
Lilly is one of the several drugmakers and research institutions that are working on vaccines, antivirals and other treatments to help those infected with the fast-spreading novel coronavirus, which has already killed over 370,000 worldwide.
Lilly developed the antibody in three months after AbCellera and the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center discovered it from a blood sample of one of the first patients who recovered from Covid-19 in the US.
An antiviral drug from Gilead Sciences called Remdesivir has shown some promise against COVID-19 and is being given to patients by some countries under compassionate or emergency use rule.
Lilly said its early stage study will assess safety and tolerability in patients hospitalized with COVID-19 and results are anticipated by the end of June.
The experimental treatment, LY-CoV555, has been developed through collaboration with privately held AbCellera Biologics, which Lilly partnered with in March.
Lilly’s treatment is an antibody directed against the spike-shaped protein structures of the virus and is designed to block it from locking on to human cells, thus neutralizing the virus.
The drugmaker said the antibody treatment was developed after it was identified from a blood sample taken from one of the first U.S. patients who recovered from the lung illness caused by the new coronavirus.
“Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of Covid-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems.”
If the antibody treatment is found to be safe in Phase I trial, Lilly will assess it in non-hospitalised Covid-19 patients and in a preventative setting.
InterGlobe’s Rahul Bhatia and C.P. Gurnani together announce
In a move that is set to transform the AI landscape, Rahul Bhatia, Group M...
Download masked Aadhaar to improve privacy
Download a masked Aadhaar from UIDAI to improve privacy. Select masking w...
Sterlite Technologies' Rs 145 crore claim against BSNL rejecte
An arbitrator has rejected broadband technology company Sterlite Technolog...
ID-REDACT® ensures full compliance with the DPDP Act for Indi
Data Safeguard India Pvt Ltd, a wholly-owned subsidiary of Data Safeguard ...
CENTRE FOR DEVELOPMENT OF TELEMATICS
HAVELLS INDIA LTD.
LENOVO GROUP LTD.
TP-LINK INDIA PVT LTD.
Technology Icons Of India 2023: Rajeev Chandrasekhar
Rajeev Chandrasekhar is the Union Minister of State for Electronics an...
Technology Icons Of India 2023: Rajiv Memani
As Chair of the EY Global Emerging Markets Committee, Rajiv connects e...
Technology Icons Of India 2023: Aalok Kumar
Aalok continues to lead the India business and further strengthen Indi...
New defence PSUs will help India become self-reliant
MIL, India’s biggest manufacturer and market leader is engaged in Pr...
Aadhaar: Architecting the World's Largest Biometric Identity System
The Unique Identification Authority of India (UIDAI) is a statutory au...
PGCIL transforming India with its wide power transmission network
Engaged in power transmission, POWERGRID or PGCIL is a stated owned In...
SUPERTRON ELECTRONICS PVT. LTD.
Supertron deals in servers, laptops, components, accessories and is a...
IRIS GLOBAL SERVICES PVT. LTD.
Iris Global services is one of the leading distribution houses that d...
SONATA INFORMATION TECHNOLOGY LIMITED
Sonata Software Limited is a leading Modernization engineering company...